We thus aimed to investigate the effect of combined treatment with PARP inhibitors and TRAIL receptor-stimulating agents in pancreatic cancer and its dependency on the BRCA2 gene status. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.